rs121964972
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PP3_ModeratePP5_Very_Strong
The NM_000071.3(CBS):c.1058C>T(p.Thr353Met) variant causes a missense change. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000071.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD3 exomes AF: 0.0000295 AC: 7AN: 237672Hom.: 0 AF XY: 0.0000383 AC XY: 5AN XY: 130450
GnomAD4 exome AF: 0.0000633 AC: 3AN: 47412Hom.: 0 Cov.: 0 AF XY: 0.0000791 AC XY: 2AN XY: 25288
GnomAD4 genome Cov.: 0
ClinVar
Submissions by phenotype
not provided Pathogenic:4
- -
CBS: PM3:Strong, PM1, PM2, PP4:Moderate, PS3:Supporting -
PS3, PM1, PM2, PM3 -
Functional studies have demonstrated that this variant results in reduced enzymatic activity (Mayfield et al., 2012); This variant is associated with the following publications: (PMID: 14635102, 20066033, 17540596, 18849566, 9156316, 23685761, 21520339, 22267502, 21626167, 24211323, 16479318, 12124992, 16205833, 31589614, 23812867) -
Classic homocystinuria Pathogenic:3
- -
- -
- -
Homocystinuria, pyridoxine-nonresponsive Pathogenic:1
- -
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
The c.1058C>T (p.T353M) alteration is located in exon 12 (coding exon 10) of the CBS gene. This alteration results from a C to T substitution at nucleotide position 1058, causing the threonine (T) at amino acid position 353 to be replaced by a methionine (M). Based on data from gnomAD, the T allele has an overall frequency of <0.01% (8/269064) total alleles studied. The highest observed frequency was 0.03% (7/24008) of African alleles. This alteration has been reported in the homozygous state and in trans with a second CBS alteration in patients with homocystinuria across various ethnicities (Kruger, 2003; Lee, 2005; Karaca, 2014; Poloni, 2018). In vitro functional studies of this alteration showed a substantial reduction in CBS activity and low growth in yeast assays (Kruger, 2003; Mayfield, 2012). In vitro expression studies of this alteration also demonstrated reduced enzyme activity in COS7 and NIH3T3 cells (Lee, 2005). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED Pathogenic:1
This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 353 of the CBS protein (p.Thr353Met). This variant is present in population databases (rs121964972, gnomAD 0.03%). This missense change has been observed in individual(s) with homocystinuria (PMID: 9156316, 11774777, 12124992, 14635102, 16205833, 16479318, 21520339, 23812867). ClinVar contains an entry for this variant (Variation ID: 131). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CBS protein function. Experimental studies have shown that this missense change affects CBS function (PMID: 9156316, 14635102, 22267502). For these reasons, this variant has been classified as Pathogenic. -
Homocystinuria Pathogenic:1
Variant summary: CBS c.1058C>T (p.Thr353Met) results in a non-conservative amino acid change located in the Pyridoxal-phosphate dependent enzyme domain (IPR001926) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.9e-05 in 237672 control chromosomes (gnomAD). c.1058C>T has been reported in the literature in multiple individuals affected with Homocystinuria (e.g. Dawson_1997, Trondle_2001, Kruger_2003, Lee_2005). These data indicate that the variant is very likely to be associated with disease. The variants' impact on protein function was evaluated in several different publications using recombinant protein recovered from E. coli cultures (Dawson_1997), yeast (Kruger_2003) and human cell lines (Lee_2005). In all instances, the variant protein had <10% of normal activity. Five ClinVar submitters have assessed the variant since 2014: all five classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at